• Korean Journal of Clinical Laboratory Science
• /
• v.54 no.1
• /
• pp.38-48
• /
• 2022

Carcinoembryonic antigen (CEA) is an oncofetal antigen primarily detected in the peripheral blood of cancer patients, particularly in those with colorectal cancer. CEA is considered a valuable target for antigen-specific immunotherapy. In this study, we induced the anti-tumor immunity for CEA through the administration of a dendritic cell (DC) vaccine. However, there was a limitation in inducing tumor regression in the DC vaccinated mice. To enhance the efficacy of anti-tumor immunity in MC38/CEA2 tumor-bearing mice, we evaluated the effects of DC vaccine in combination with cyclophosphamide (CYP). Administration of CYP 100 mg/kg in mice resulted in significant inhibition of tumor growth in the 2-day tumor model, whereas a lower inhibition of tumor growth was seen in the 10-day tumor model. Therefore, the 10-day tumor model was selected for testing chemo-immunotherapy. The combined CYP and DC vaccine not only increased tumor antigen-specific immune responses but also induced synergistic anti-tumor immunity. Furthermore, the adverse effects of CYP such as weight loss and immunosuppression by regulatory T cells and myeloid-derived suppressor cells showed a significant reduction in the combined chemo-immunotherapy treatment compared with CYP alone. Our data suggest that chemoimmunotherapy with the DC vaccine may offer a new therapeutic strategy to induce a potent anti-tumor effect and reduce the adverse effects of chemotherapy.

• Korean Journal of Bronchoesophagology
• /
• v.3 no.2
• /
• pp.245-252
• /
• 1997

실험실에서 면역세포가 종양세포를 죽일 수 있다든가 혹은 드물지만 암 환자에서 암이 자연적으로 소실되었다는 임상적 보고 그리고 AIDS 환자와 같은 면역계의 장애를 가진 환자에서 Kaposi 육종, 특정 형태의 림프종이 더 잘 생긴다는 것 등으로 미루어 보면 동물이나 인간에 발생하는 암에 대해 어느 정도의 면역반응이 일어나는 것은 분명하다. 인체는 규칙적으로 암세포를 생산하지만 면역계에 의해 제거되는 것으로 추측된다. 그러나 아직도 면역계가 어떻게 암을 억제하는지 그리고 면역계가 암발생을 억제하는데 왜 실패하는지에 대해서는 정확히 모르고 있다. 이러한 의문점들은 앞으로 종양 면역학이 규명해야 할 과제이다.

• Nuclear Medicine and Molecular Imaging
• /
• v.43 no.1
• /
• pp.60-71
• /
• 2009

Purpose: We assessed the absorbed dose to the tumor ($Dose_{tumor}$) by using pretreatment FDG-PET and whole-body (WB) planar images in repeated radioimmunotherapy (RIT) with $^{131}I$ rituximab for NHL. Materials and Methods: Patients with NHL (n=4) were administered a therapeutic dose of $^{131}I$ rituximab. Serial WB planar images alter RIT were acquired and overlaid to the coronal maximum intensity projection (MIP) PET image before RIT. On registered MIP PET and WB planar images, 2D-ROls were drawn on the region of tumor (n=7) and left medial thigh as background, and $Dose_{tumor}$ was calculated. The correlation between $Dose_{tumor}$ and the CT-based tumor volume change alter RIT was analyzed. The differences of $Dose_{tumor}$ and the tumor volume change according to the number of RIT were also assessed. Results: The values of absorbed dose were $397.7{\pm}646.2cGy$ ($53.0{\sim}2853.0cGy$). The values of CT-based tumor volume were $11.3{\pm}9.1\;cc$ ($2.9{\sim}34.2cc$), and the % changes of tumor volume before and alter RIT were $-29.8{\pm}44.3%$ ($-100.0%{\sim}+42.5%$), respectively. $Dose_{tumor}$ and the tumor volume change did not show the linear relationship (p>0.05). $Dose_{tumor}$ and the tumor volume change did not correlate with the number of repeated administration (p>0.05). Conclusion: We could determine the position and contour of viable tumor by MIP PET image. And, registration of PET and gamma camera images was possible to estimate the quantitative values of absorbed dose to tumor.

• The Journal of the Korean bone and joint tumor society
• /
• v.13 no.2
• /
• pp.67-74
• /
• 2007

Purpose: To evaluate association of giant cell tumors recurrence between markers of proliferation cells (MCM3, Ki-67 and HH3) Materials and Methods: Ten case of giant cell tumor of bone were reviewed. The patients were six males and four females (mean age: 33 yrs). All patients were done operation after biopsy. The radiologic grading was determined according to Enneking grading system. The immunohistochemical stains of MCM3, HH3, and Ki-67 were done with Microarray block. Results: The three cases of 10 cases (30%) were recurred at same sites. Two case of recurrence was grade II according to radiologic features. The remaining case was grade I. The expression rate of immunohistochemical markers in radiologic grade 2 and 3 were more increased than grade 1. But there was not association between radiologic grading and proliferation of tumor cells because result data was not coherence. Mean MCM3 labeling index of non-recurred case was 11.2%, recurred case was 7.2%. Ki-67 was 12% vs. 8.9%, respectively and HH3 was 66.9 % vs. 75.4%, respectively. Thus there was no association between local recurrence and immunohistochemical Ki-67, MCM3 expression rate. But HH3 marker expression rate was increased in recurred cases compared to non-recurred cases. Conclusion: Our study suggests that HH3 immunohistochemical marker can be a useful prognostic factor.

• Journal of Life Science
• /
• v.28 no.8
• /
• pp.992-998
• /
• 2018

Cancer cells grow in an environment composed of various components that supports tumor growth. Major cell types in the tumor microenvironment are fibroblast, endothelial cells and immune cells. All of these cells communicate with cancer cells. Among infiltrating immune cells as an abundant component of solid tumors, macrophages are a major component of the tumor microenvironment and orchestrates various aspects of immunity. The complex balance between pro-tumoral and anti-tumoral effects of immune cell infiltration can create a chronic inflammatory microenvironment essential for tumor growth and progression. Macrophages express different functional programs in response to microenvironmental signals, defined as M1 and M2 polarization. Tumor-associated macrophages (TAM) secret many cytokines, chemokines and proteases, which also promote tumor angiogenesis, growth, metastasis and immunosuppression. TAM have multifaceted roles in the development of many tumor types. TAM also interact with cancer stem cells. This interaction leads to tumorigenesis, metastasis, and drug resistance. TAM obtain various immunosuppressive functions to maintain the tumor microenvironment. TAM are characterized by their heterogeneity and plasticity, as they can be functionally reprogrammed to polarized phenotypes by exposure to cancer-related factors, stromal factors, infections, or even drug interventions. Because TAMs produce tumor-specific chemokines by the stimulation of stromal factors, chemokines might serve as biomarkers that reflect disease activity. The evidence has shown that cancer tissues with high infiltration of TAM are associated with poor patient prognosis and resistance to therapies. Targeting of TAM in tumors is considered a promising therapeutic strategy for anti-cancer treatment.

• Journal of Life Science
• /
• v.29 no.7
• /
• pp.824-835
• /
• 2019

In recent decades, oncolytic viruses (OVs) have extensively been investigated as a potential cancer drug. Oncolytic viruses have primarily the unique advantage in the fact that they can only infect and destroy cancer cells. Secondary, oncolytic viruses induce the activation of specific adaptive immunity which targets tumor-associated antigens that were hidden during the initial cancer progression. In 2015, one genetically modified oncolytic virus, talimogene laherparepvec (T-VEC), was approved by the American Food and Drug Administration (FDA) for the treatment of melanoma. Currently, various oncolytic viruses are being investigated in clinical trials as monotherapy or in combination with preexistent cancer therapies like immunotherapy, radiotherapy or chemotherapy. The efficacy of oncolytic virotherapy relies on the balance between the induced anti-tumor immunity and the anti-viral response. Despite the revolutionary outcome, the development of oncolytic viruses for the treatment of cancer faces a number of obstacles such as delivery method, neutralizing antibodies and induction of antiviral immunity due to the complexity, variability and reactivity of tumors. Intratumoral administration has been successful reducing considerably solid tumors with no notable side effects unfortunately some tumors are not accessible (brain) and require a systemic administration of the oncolytic viruses. In order to overcome these hurdles, various strategies to enhance the efficacy of oncolytic viruses have been developed which include the insertion of transgenes or combination with immune-modulatory substances.

• The Journal of the Korean bone and joint tumor society
• /
• v.9 no.1
• /
• pp.77-83
• /
• 2003

Aggressive fibromatosis is a rare soft tissue tumor with locally invasive and infiltrative characteristics. The mechanism of this invasive nature was not reported until now. Mutations or reduction of PTEN, tumor suppressor gene, in cancer tissues, have been found to be associated with invasiveness and metastatic properties of cancer cells. To know the pattern of expression of PTEN in aggressive fibromatosis, we analysed the expression of PTEN with immunohistochemical stain and immunoblotting. PTEN was homogeneously expressed in the normal musculoaponeurotic tissues, but absent or very faint in tissues of patients with aggressive fibromatosis as evidenced by western blot analysis and immunohistochemical examinations. Although the meaning of decreased PTEN expression in aggressive fibromatosis is not certain, it might be involved in the growth of the aggressive fibromatosis, and associated with phenotype of aggressive fibromatosis.

• 대한두경부종양학회:학술대회논문집
• /
• 1998.05a
• /
• pp.115-117
• /
• 1998

• Journal of Life Science
• /
• v.3 no.3
• /
• pp.136-142
• /
• 1993

Cytokine은 여러 가지 세포성 면역을 발현시키는 작용물질로서, 혹은 체액성 면역에 있어서 그 조절기능에 관여하는 작용물질로서 주목을 받고 있으며, 그 대부분은 직접적이거나 간접적으로 감염이나 종양에 대한 생체방어기구에 대하여 중요한 역할을 갖는 것이 밝혀지고 있다. Cytokine의 생체내에서의 역할은 감염 방어기구에 관여하고, 항종양 면역에 관여한다. 최근에는 cytokine과 내분비계의 호르몬이 상호작용을 하고 있다는 것이 밝혀지고 있다. 내분비계의 gormone과 cytokine 간에는 일방향성이 아니라 이방향성의 상호작용이 있다고 말할 수 있다.

• Journal of Chest Surgery
• /
• v.33 no.11
• /
• pp.922-924
• /
• 2000

양성 신경초종(benign schwannoma)이 식도를 포함한 위장관계에 발생하는 경우는 매우 드물다. 이러한 양성식도 신경초종은 확진을 위해 면역 조직 화학적 염색을 필요로 한다. 정기 신체 검진상 우연히 발견된 66세여자 환자의 식도 점막하 종양에 대해 우측 후측부 개흉을 통한 종양 적출을 시행하였으며, 술후 면역 조직 화학적 병리 검사를 통하여 식도의 양성 신경초종임을 확인하였고, 환자는 술후 1년째 재발없이 외래 추적 관찰을 받고 있다.